Skip to content
Screener

Aurinia Pharmaceuticals AUPH Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$77.7MBeat by $726.3K
EPS$0.25Beat by $0.07
Revenue estimate$77.0M
EPS estimate$0.18

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$83.6M
EPS estimate$0.21

Financials

Q1 2026

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.97B+78.5%
Enterprise value$2.01B+78.3%
P/E6.6×-21.1×
P/S6.6×+2.1×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Segments

By product

See full
License, collaboration and royalty revenue$4.1M+66.1%

FAQ

When did Aurinia Pharmaceuticals report Q1 2026 earnings?
Aurinia Pharmaceuticals (AUPH) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Aurinia Pharmaceuticals's Q1 2026 revenue and EPS?
Aurinia Pharmaceuticals reported revenue of $77.7M and eps of $0.25 for Q1 2026.
Did Aurinia Pharmaceuticals beat estimates in Q1 2026?
Revenue beat the consensus estimate of $77.0M by $726.3K. EPS beat the consensus estimate of $0.18 by $0.07.
How did Aurinia Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 24.4% from $62.5M a year earlier and eps grew 56.3% from $0.16.
Where can I find Aurinia Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001600620-26-000048) and the 10-Q periodic report (0001600620-26-000049) directly on SEC EDGAR. The filing index links above go to sec.gov.